Publication

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors not recorded

Cancer Discov2011PMID 22328973PMC3274752stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (14)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 14

cancerLung Adenosquamous Carcinomacivic_curation1.00
cancerLung Non-Small Cell Carcinomacivic_curation1.00
cancerLung Squamous Cell Carcinomacivic_curation1.00
cancerMalignant Neoplasmcivic_curation1.00
drugDasatinibcivic_curation1.00
drugErlotinibcivic_curation1.00
geneDDR2civic_curation1.00
variantDDR2 G253Ccivic_curation1.00
variantDDR2 G505Scivic_curation1.00
variantDDR2 G774Vcivic_curation1.00
variantDDR2 I638Fcivic_curation1.00
variantDDR2 L239Rcivic_curation1.00
variantDDR2 L63Vcivic_curation1.00
variantDDR2 S768Rcivic_curation1.00

Curated evidence

Evidence citing this paper (8)

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DDR2 L239R1
Dasatinib	Lung Adenosquamous CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID270 The HCC-366 lung adenosquamous carcinoma cell line, containing the DDR2 L239R mutation was shown to be sensitive (IC50 140nm) to dasatinib in-vitro. The authors were unable to establish tumors using t… (full text at CIViC) PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
DDR2 G505S1
Dasatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID267 In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
DDR2 G774V1
Dasatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID268 Ba/F3 cells expressing the G774V mutation were sensitive to the tyrosine kinase inhibitor dasatinib while wild-type expressing cells were not, as measured in a proliferation assay. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
DDR2 L63V1
Dasatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID271 In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
DDR2 I638F1
Dasatinib	Lung Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID269 The NCI-H2286 lung squamous cell carcinoma cell line, containing the DDR2 I638F mutation was shown to be sensitive (IC50 139nm) to dasatinib in-vitro. Dasatanib sensitivity was demonstrated in-vivo us… (full text at CIViC) PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
DDR2 S768R1
Dasatinib + ErlotinibCombination	Lung Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID272 In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
KRAS G12S1
Dasatinib	Lung Squamous Cell Carcinoma	Predictive	D	Supports Resistance	—	submitted	EID4020 In an in vitro study, the A549 cell line, which harbors the KRAS G12S mutation, was found to have insensitivity to dasatinib treatment (IC50: 7.4 uM). In in vivo experiments, KRAS G12S expressing A549… (full text at CIViC) PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
DDR2 G253C1
Dasatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID266 Ba/F3 cells expressing the G253C mutation were sensitive to the tyrosine kinase inhibitor dasatinib while wild-type expressing cells were not, as measured in a proliferation assay. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic